Corvus Pharmaceuticals, Inc. Variable Lease, Cost
Corvus Pharmaceuticals, Inc. (CRVS) reported Variable Lease, Cost of $420.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-19.
Discontinued › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2024-03-19
- Corvus Pharmaceuticals, Inc. variable lease, cost for the quarter ending 2023-03-31 was $111.00K, a 2.78% increase year-over-year.
- Corvus Pharmaceuticals, Inc. variable lease, cost for the quarter ending 2022-12-31 was $110.00K, a 12.24% increase year-over-year.
- Corvus Pharmaceuticals, Inc. variable lease, cost for the quarter ending 2022-09-30 was $108.00K, a 10.20% increase year-over-year.
- Corvus Pharmaceuticals, Inc. variable lease, cost for the quarter ending 2022-06-30 was $25.00K, a 74.49% decline year-over-year.
- Corvus Pharmaceuticals, Inc. variable lease, cost for fiscal 2023 was $420.00K, a 19.66% increase from fiscal 2022.
- Corvus Pharmaceuticals, Inc. variable lease, cost for fiscal 2022 was $351.00K, a 11.36% decline from fiscal 2021.
- Corvus Pharmaceuticals, Inc. variable lease, cost for fiscal 2021 was $396.00K, a 12.82% increase from fiscal 2020.
- Corvus Pharmaceuticals, Inc. variable lease, cost for fiscal 2020 was $351.00K, a 8.33% increase from fiscal 2019.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2023-12-31 | $420.00K 10-K · filed 2024-03-19 | |||
| 2023-03-31 | $111.00K 10-Q · filed 2023-05-08 | $221.00K derived: sum of 2 quarters · filed 2024-03-19 | $329.00K derived: sum of 3 quarters · filed 2024-03-19 | $354.00K derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-12-31 | $110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $218.00K derived: sum of 2 quarters · filed 2024-03-19 | $243.00K derived: sum of 3 quarters · filed 2024-03-19 | $351.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $108.00K 10-Q · filed 2022-11-03 | $133.00K derived: sum of 2 quarters · filed 2022-11-03 | $241.00K 10-Q · filed 2022-11-03 | $339.00K derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-06-30 | $25.00K 10-Q · filed 2022-08-08 | $133.00K 10-Q · filed 2022-08-08 | $231.00K derived: sum of 3 quarters · filed 2024-03-19 | $329.00K derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-03-31 | $108.00K 10-Q · filed 2023-05-08 | $206.00K derived: sum of 2 quarters · filed 2024-03-19 | $304.00K derived: sum of 3 quarters · filed 2024-03-19 | $402.00K derived: sum of 4 quarters · filed 2024-03-19 |
| 2021-12-31 | $98.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $196.00K derived: sum of 2 quarters · filed 2024-03-19 | $294.00K derived: sum of 3 quarters · filed 2024-03-19 | $396.00K 10-K · filed 2024-03-19 |
| 2021-09-30 | $98.00K 10-Q · filed 2022-11-03 | $196.00K derived: sum of 2 quarters · filed 2022-11-03 | $298.00K 10-Q · filed 2022-11-03 | $386.00K derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-06-30 | $98.00K 10-Q · filed 2022-08-08 | $200.00K 10-Q · filed 2022-08-08 | $288.00K derived: sum of 3 quarters · filed 2023-03-28 | $375.00K derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-03-31 | $102.00K 10-Q · filed 2022-05-05 | $190.00K derived: sum of 2 quarters · filed 2023-03-28 | $277.00K derived: sum of 3 quarters · filed 2023-03-28 | $364.00K derived: sum of 4 quarters · filed 2023-03-28 |
| 2020-12-31 | $88.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $175.00K derived: sum of 2 quarters · filed 2023-03-28 | $262.00K derived: sum of 3 quarters · filed 2023-03-28 | $351.00K 10-K · filed 2023-03-28 |
| 2020-09-30 | $87.00K 10-Q · filed 2021-11-01 | $174.00K derived: sum of 2 quarters · filed 2021-11-01 | $263.00K 10-Q · filed 2021-11-01 | $343.00K derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-06-30 | $87.00K 10-Q · filed 2021-08-02 | $175.00K 10-Q · filed 2021-08-02 | $256.00K derived: sum of 3 quarters · filed 2022-03-10 | $337.00K derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-03-31 | $88.00K 10-Q · filed 2021-04-29 | $169.00K derived: sum of 2 quarters · filed 2022-03-10 | $250.00K derived: sum of 3 quarters · filed 2022-03-10 | $331.00K derived: sum of 4 quarters · filed 2022-03-10 |
| 2019-12-31 | $81.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $162.00K derived: sum of 2 quarters · filed 2022-03-10 | $243.00K derived: sum of 3 quarters · filed 2022-03-10 | $324.00K 10-K · filed 2022-03-10 |
| 2019-09-30 | $81.00K 10-Q · filed 2020-10-29 | $162.00K derived: sum of 2 quarters · filed 2020-10-29 | $243.00K 10-Q · filed 2020-10-29 | $317.00K derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-06-30 | $81.00K 10-Q · filed 2020-07-30 | $162.00K 10-Q · filed 2020-07-30 | $236.00K derived: sum of 3 quarters · filed 2021-03-25 | $309.00K derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-03-31 | $81.00K 10-Q · filed 2020-04-30 | $155.00K derived: sum of 2 quarters · filed 2021-03-25 | $228.00K derived: sum of 3 quarters · filed 2021-03-25 | $301.00K derived: sum of 4 quarters · filed 2021-03-25 |
| 2018-12-31 | $74.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $147.00K derived: sum of 2 quarters · filed 2021-03-25 | $220.00K derived: sum of 3 quarters · filed 2021-03-25 | $296.00K 10-K · filed 2021-03-25 |
| 2018-09-30 | $73.00K 10-Q · filed 2019-10-29 | $146.00K derived: sum of 2 quarters · filed 2019-10-29 | $222.00K 10-Q · filed 2019-10-29 | |
| 2018-06-30 | $73.00K 10-Q · filed 2019-08-01 | $149.00K 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | $75.00K 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $281.00K 10-K · filed 2020-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |